---
title: "ATP5E"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "#Gene ATP5E "
tags: ['ATP5E', 'MitochondrialDisorders', 'EnergyGeneration', 'GeneticMutation', 'Prognosis', 'SymptomaticCare', 'DrugResponse', 'GeneReviews']
---

#Gene ATP5E 

###Information
ATP5E gene provides instructions that are necessary for coding the protein that is involved in the assembly of the ATP synthase enzyme, which helps in the generation of energy from the mitochondrial membrane. 

###External IDs
- HGNC: 849
- NCBI Entrez: 513 
- Ensembl: ENSG00000130522 
- OMIM: 602141
- UniProtKB/Swiss-Prot: O75748

###AA mutation list 
- c.137C>T (p.Thr46Met) rs121434554
- c.548C>T (p.Ser183Leu) rs140153628
- c.919C>T (p.Ala307Val) rs121434553

###Somatic SNVs/InDels 
- c.144G>A (p.Gly48Arg) rs1057519704
- c.145G>A (p.Gly49Arg) rs141696559

###Related Diseases 
- ATP synthase deficiency syndromes 
- Mitochondrial Complex V (ATP Synthase) Deficiency, Nuclear Type 5

###Treatment and Prognosis
Currently, there is no treatment for ATP5E gene-related diseases. However, effective management and symptomatic care can improve the prognosis for the affected individuals.

###Drug response
There is no specific drug for the treatment of ATP5E gene-related disorders.

###References
- Cohen, B. H., et al. (2009). "Consensus statement on mitochondrial myopathies." J Child Neurol 24(4): 426-441. DOI: 10.1177/0883073808327838
- Pareyson D., and Saveri P. (2015). "Mitochondrial Complex V (ATP Synthase) Deficiency, Nuclear Type 5." GeneReviewsÂ® [Internet]. PMID: 26308338

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**